Recombinant Human CEACAM-19 Fc Chimera Protein, CF

Immobilized Recombinant Human CEACAM-19 (Catalog # 9397-CM)enhances L Cells mouse fibroblasts adhesion. The ED50 for this effect is0.4-2.4 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CEACAM-19 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of the L Cells mouse fibroblast cell line. The ED₅₀ for this effect is 0.4-2.4 μg/mL
• Source: Human embryonic kidney cell, HEK293-derived human CEACAM-19 protein
  

  Human CEACAM-19 (Ala33-Gly157) Accession # Q7Z692-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q7Z692-1
• N-terminal Sequence: Ala33
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 42-56 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CEACAM-19 Fc Chimera Protein, CF

• carcinoembryonic antigen-related cell adhesion molecule 19
• CEACAM19
• CEACAM-19
• CEAL1

Background

Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).

1. Schorilas, A. et al. (2003) Gene 310:79.
2. Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
3. Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
4. Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
5. Obrink, B. (1997) Curr Opin Cell Biol 9:616.
6. Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
7. Michaelidou, K. et al. (2013) Int J Oncol 42:1770.

Bioinformatics

• Uniprot:
  • Q7Z692-1()